Why did EPS grow faster than net income in the second quarter?

Net income attributable to HCA grew 13.1%, while diluted EPS grew 23.5%. The gap is mainly share count reduction: diluted shares fell from 264.1 million to 241.9 million, about 8.4%, as HCA repurchased stock aggressively over the past year. Lower gains on facility sales also played a small role, as Q2 2024 included a $0.03 per share gain versus a $0.01 per share loss in Q2 2025.

How much did HCA raise its 2025 guidance, and what drove it?

The EPS guidance range rose to $25.50-$27.00 from $24.05-$25.85, a midpoint increase of about 6%. Adjusted EBITDA guidance rose to $14.7-$15.3 billion from $14.3-$15.1 billion, and revenue guidance rose to $74-$76 billion from $72.8-$75.8 billion. The filing attributes the update to the strong first-half results, but it does not provide a detailed bridge. Guidance assumes a mostly stable operating environment and continued effects from the 2024 hurricanes.

Is HCA's balance sheet a concern for investors?

Leverage is high. Total debt is $44.5 billion against $939 million of cash, and the stockholders' deficit attributable to HCA widened to $4.4 billion from $2.5 billion at year-end 2024, largely reflecting buybacks. Short-term debt and current maturities rose to $5.1 billion. Operating cash flow of $5.9 billion in the first half and $2.5 billion of Q2 repurchases show HCA can fund its obligations, but the company is returning capital while carrying significant leverage.

What policy and payer risks does the filing highlight?

The forward-looking statements flag the expiration of enhanced premium tax credits for marketplace enrollees, the effects of the One Big Beautiful Bill Act (OBBBA), possible Medicare and Medicaid payment reductions (including supplemental and state directed payments), federal sequestration, and the risk of rising uninsured and underinsured patients. They also cite tariffs and supply chain disruptions. Management says it is developing resiliency plans to offset these effects, but the filing does not quantify their impact.

What are the key details of the dividend and capital return program?

HCA declared a quarterly cash dividend of $0.72 per share, payable September 30, 2025 to stockholders of record at the close of business on September 16, 2025. Dividends are subject to Board discretion and are expected to be funded from cash and operating cash flow. Alongside the dividend, HCA repurchased $2.5 billion of stock in Q2 and has $5.75 billion of authorization remaining, which makes buybacks a larger component of shareholder returns than the dividend, which paid $351 million in the first half.

HCA 8-K: Earnings & Results & Regulation FD

01—Abstract

Summary

Summary of the 8-K filed July 25, 2025. Cited figures are marked; the original filing is the authoritative source.

HCA Healthcare reported strong second-quarter 2025 results, with revenues up 6.4% to $18.605 billion^a and net income attributable to HCA up 13.1% to $1.653 billion.

Diluted EPS rose 23.5% to $6.83^b, and adjusted EBITDA increased 8.4% to $3.849 billion, with the adjusted EBITDA margin expanding to 20.7% from 20.3%. Operating cash flow more than doubled to $4.210 billion from $1.971 billion. EPS growth outpaced net income growth largely because diluted shares fell about 8% year over year, from 264.1 million to 241.9 million, reflecting aggressive buybacks.

Same facility admissions grew 1.8%, and same facility revenue per equivalent admission rose 4.0%, so pricing and mix contributed more to growth than volume. Management raised its 2025 guidance across the board. Revenue is now expected at $74.0 to $76.0 billion^c, adjusted EBITDA at $14.7 to $15.3 billion, and diluted EPS at $25.50 to $27.00, up from $24.05 to $25.85.

The midpoint EPS raise is roughly 6%. Capital expenditures are estimated at about $5.0 billion^d. The Board declared a quarterly dividend of $0.72 per share, payable September 30, 2025 to holders of record on September 16, 2025.

Balance sheet leverage remains high. Total debt was $44.5 billion against $939 million of cash, and HCA reported a stockholders' deficit attributable to the company of $4.4 billion, which widened from $2.5 billion at year-end 2024.

Short-term debt and current maturities rose to $5.1 billion. Investors should weigh strong cash generation and shareholder returns, including $5.0 billion of repurchases in the first half, against this leverage and the policy and payer uncertainties cited in the forward-looking statements, such as enhanced premium tax credit expirations, Medicaid program changes, and the OBBBA legislation.

02—Key points

Key Highlights

Q2 2025 revenue rose 6.4% to $18.605 billion, and net income attributable to HCA rose 13.1% to $1.653 billion.
Diluted EPS increased 23.5% to $6.83 (adjusted $6.84, up 24.4%), helped by a roughly 8% reduction in diluted share count year over year.
Adjusted EBITDA grew 8.4% to $3.849 billion, with the margin expanding to 20.7% from 20.3%.
2025 guidance raised: EPS to $25.50-$27.00 (from $24.05-$25.85), adjusted EBITDA to $14.7-$15.3 billion (from $14.3-$15.1 billion), revenue to $74-$76 billion, and net income to $6.11-$6.48 billion.
Operating cash flow was $4.210 billion in Q2 versus $1.971 billion a year earlier; first-half operating cash flow was $5.861 billion.
HCA repurchased 7.03 million shares for $2.505 billion in Q2 ($5.011 billion year to date) and has $5.753 billion remaining under its authorization.
Quarterly dividend of $0.72 per share declared, payable September 30, 2025 to holders of record on September 16, 2025; total debt stands at $44.5 billion against $939 million of cash.

03—Questions

Frequently Asked Questions

Why did EPS grow faster than net income in the second quarter?
Net income attributable to HCA grew 13.1%, while diluted EPS grew 23.5%. The gap is mainly share count reduction: diluted shares fell from 264.1 million to 241.9 million, about 8.4%, as HCA repurchased stock aggressively over the past year. Lower gains on facility sales also played a small role, as Q2 2024 included a $0.03 per share gain versus a $0.01 per share loss in Q2 2025.
How much did HCA raise its 2025 guidance, and what drove it?
The EPS guidance range rose to $25.50-$27.00 from $24.05-$25.85, a midpoint increase of about 6%. Adjusted EBITDA guidance rose to $14.7-$15.3 billion from $14.3-$15.1 billion, and revenue guidance rose to $74-$76 billion from $72.8-$75.8 billion. The filing attributes the update to the strong first-half results, but it does not provide a detailed bridge. Guidance assumes a mostly stable operating environment and continued effects from the 2024 hurricanes.
Is HCA's balance sheet a concern for investors?
Leverage is high. Total debt is $44.5 billion against $939 million of cash, and the stockholders' deficit attributable to HCA widened to $4.4 billion from $2.5 billion at year-end 2024, largely reflecting buybacks. Short-term debt and current maturities rose to $5.1 billion. Operating cash flow of $5.9 billion in the first half and $2.5 billion of Q2 repurchases show HCA can fund its obligations, but the company is returning capital while carrying significant leverage.
What policy and payer risks does the filing highlight?
The forward-looking statements flag the expiration of enhanced premium tax credits for marketplace enrollees, the effects of the One Big Beautiful Bill Act (OBBBA), possible Medicare and Medicaid payment reductions (including supplemental and state directed payments), federal sequestration, and the risk of rising uninsured and underinsured patients. They also cite tariffs and supply chain disruptions. Management says it is developing resiliency plans to offset these effects, but the filing does not quantify their impact.
What are the key details of the dividend and capital return program?
HCA declared a quarterly cash dividend of $0.72 per share, payable September 30, 2025 to stockholders of record at the close of business on September 16, 2025. Dividends are subject to Board discretion and are expected to be funded from cash and operating cash flow. Alongside the dividend, HCA repurchased $2.5 billion of stock in Q2 and has $5.75 billion of authorization remaining, which makes buybacks a larger component of shareholder returns than the dividend, which paid $351 million in the first half.

04—Continue

← View all 8-K filings